Background: Dust generated during the processing of building materials enterprises can pose a serious health risk. The study aimed to compare and analyze the results of ART and the Monte Carlo model for the dust exposure assessment in building materials enterprises, to derive the application scope of the two models. Methods: First, ART and the Monte Carlo model were used to assess the exposure to dust in each of the 15 building materials enterprises. Then, a comparative analysis of the exposure assessment results was conducted. Finally, the model factors were analyzed using correlation analysis and the scope of application of the models was determined. Results: The results show that ART is mainly influenced by four factors, namely, localized controls, segregation, dispersion, surface contamination, and fugitive emissions, and applies to scenarios where the workplace information of the building materials enterprises is specific and the average dust concentration is greater than or equal to 1.5 mg/m3. The Monte Carlo model is mainly influenced by the dust concentration in the workplace of building materials enterprises and is suitable for scenarios where the dust concentration in the workplace of the building materials enterprises is relatively uniform and the average dust concentration is less than or equal to 6mg/m3. Conclusion ART is most accurate when workplace information is specific and average dust concentration is > 1.5 mg/m3; whereas, The Monte Carlo model is the best when dust concentration is homogeneous and average dust concentration is < 6 mg/m3.

CUDC-101, an effective and multi-target inhibitor of epidermal growth factor receptor (EGFR), histone deacetylase (HDAC), and human epidermal growth factor receptor 2 (HER2), has been reported to inhibit many kinds of cancers, such as acute promyelocytic leukemia and non-Hodgkin's lymphoma. However, no studies have yet investigated whether CUDC-101 is effective against myeloma. Herein, we proved that CUDC-101 effectively inhibits the proliferation of multiple myeloma (MM) cell lines and induces cell apoptosis in a time- and dose-dependent manner. Moreover, CUDC-101 markedly blocked the signaling pathway of EGFR/phosphoinositide-3-kinase (PI3K) and HDAC, and regulated the cell cycle G2/M arrest. Moreover, we revealed through in vivo experiment that CUDC-101 is a potent anti-myeloma drug. Bortezomib is one of the important drugs in MM treatment, and we investigated whether CUDC-101 has a synergistic or additive effect with bortezomib. The results showed that this drug combination had a synergistic anti-myeloma effect by inducing G2/M phase blockade. Collectively, our findings revealed that CUDC-101 could act on its own or in conjunction with bortezomib, which provides insights into exploring new strategies for MM treatment.
Humans ; Antineoplastic Agents/therapeutic use* ; Apoptosis ; Bortezomib/pharmacology* ; Cell Line, Tumor ; Cell Proliferation ; ErbB Receptors/antagonists & inhibitors* ; G2 Phase Cell Cycle Checkpoints ; Histone Deacetylase Inhibitors/pharmacology* ; Histone Deacetylases/metabolism* ; M Cells ; Multiple Myeloma/drug therapy*